10 Best CEFs This Month: Average Yield Of 10% (September 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and nearly a 6% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Sep 26, 2026

HQL: The Rally That Makes Growth Harder (Rating Downgrade)

abrdn Life Sciences Investors Fund is downgraded to Hold after a 57.6% total return and a rally driven by sector-wide capital rotation. HQL's 12.5% yield is supported by strong net realized gains, but its reliance on these gains and a higher distribution limit future price appreciation. The fund trades at a 5.95% discount to NAV, the lowest in three years, making new accumulation less attractive amid potential sentiment cooling.

Seeking Alpha • Sep 15, 2026

10 Best CEFs This Month: Average Yield Of Near 10% (August 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% yield and nearly 5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Aug 29, 2026

10 Best CEFs This Month: Average Yield Of Near 10% (July 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and nearly 7.7% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Jul 25, 2026

HQL: Attractive Outlook With Growth Of GLP-1 Market

I maintain a buy rating on abrdn Life Sciences Investors Fund (HQL), which trades at an 8.49% discount to NAV and offers a 12.6% yield. HQL is positioned to benefit from the accelerating GLP-1 market, with top holdings in high-growth biotech names and a portfolio heavily weighted to biotechnology. While total returns have been competitive, HQL's high distributions come at the expense of capital appreciation, making it best suited for income-focused investors.

Seeking Alpha • May 19, 2026

How To Invest $100,000 Today: 5 Strategies For Success

The market environment is challenging, to say the least. We discuss how one should invest in today's market. The article presents five different investment strategies, including a fixed-income strategy, high-income strategy, sleep-well-at-night strategy, growth-focused strategy, and the Near-Perfect Portfolio strategy. Selecting a strategy aligned with personal risk tolerance and sticking to it through cycles is critical for long-term success.

Seeking Alpha • Apr 25, 2026

10 Best CEFs This Month: Average Yield Of 10% (March 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and 10.8% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Mar 29, 2026

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Feb 28, 2026

How We're Playing ‘AI 2.0' For Big Dividend Payouts

If you're wondering whether the rally in tech stocks is fading, well, it is.

Forbes • Jan 31, 2026

HQL: Dividend Can Be Sustained Through 2026

abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL's income-focused strategy relies on net realized gains, supporting robust distributions but exposing NAV to downside risk in weak markets. Biotech dominates HQL's portfolio (82.7%), with top holdings like AMGN and REG, and no direct leverage, but interest rate sensitivity remains.

Seeking Alpha • Jan 28, 2026